Cited by 267Nanoparticle-Based Drug DeliveryRadiation Therapy and DosimetryLung Cancer Diagnosis and Treatment

The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.

Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer

Open access

Werner, Michael E., Cummings, Natalie D., Sethi, Manish, Wang, Edina C., Sukumar, Rohit, Moore, Dominic T., Wang, Andrew Z.·2013·International Journal of Radiation Oncology*Biology*Physics

DOI 10.1016/j.ijrobp.2013.02.009PMC PMC3750707

Open this paper in CoChat — free account

Abstract

Purpose A key research objective in radiation oncology is to identify agents that can improve chemoradiation therapy. Nanoparticle (NP) chemotherapeutics possess several properties, such as preferential accumulation in tumors, that are uniquely suited for chemoradiation therapy. To facilitate the clinical translation of NP chemotherapeutics in chemoradiation therapy, we conducted preclinical evaluation of Genexol-PM, the only clinically approved NP chemotherapeutic with a controlled drug release profile, as a radiosensitizer using non-small cell lung cancer (NSCLC) as a model disease.Methods and materials The physical characteristics and drug release profile of Genexol-PM were characterized. Genexol-PM's efficacy as a radiosensitizer was evaluated in vitro using NSCLC cell lines and in vivo using mouse xenograft models of NSCLC. Paclitaxel dose to normal lung and liver after Genexol-PM administration were quantified and compared with that after Taxol administration.Results Genexol-PM has a size of 23.91 ± 0.41 nm and surface charge of -8.1 ± 3.1 mV. It releases paclitaxel in a controlled release profile. In vitro evaluation of Genexol-PM as a radiosensitizer showed it is an effective radiosensitizer and is more effective than Taxol, its small molecule counterpart, at the half maximal inhibitory concentration. In vivo study of Genexol-PM as a radiosensitizer demonstrated that it is more effective as a radiosensitizer than Taxol. We also found that Genexol-PM leads to lower paclitaxel exposure to normal lung tissue than Taxol at 6 hours postadministration.Conclusions We have demonstrated that Genexol-PM is more effective than Taxol as a radiosensitizer in the preclinical setting and holds high potential for clinical translation. Our data support the clinical evaluation of Genexol-PM in chemoradiation therapy for NSCLC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ijrobp.2013.02.009

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M. H., Pajak, T. F., Weber, R. S., Morrison, W. H., Glisson, B. S., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,161
Analysis of serial measurements in medical research.
Matthews, J. N. S., Altman, D. G., Campbell, M. J., & Royston, P. J. (1990) · BMJ · doi:10.1136/bmj.300.6719.230 · Cited by 3,137
Nanoparticles in Medicine: Therapeutic Applications and Developments
Zhang, L., Gu, F., Chan, J. M., Wang, A. Z., Langer, R., & Farokhzad, O. C. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100400 · Cited by 2,685
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic‐Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,774
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,739
Nanoparticle Delivery of Cancer Drugs
Wang, A. Z., Langer, R., & Farokhzad, O. C. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-040210-162544 · Cited by 1,575
Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery
O’Connell, M. J., Martenson, J. A., Wieand, H. S., Krook, J. E., Macdonald, J. S., Haller, D. G., Mayer, R. J., Gunderson, L. L., & Rich, T. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408253310803 · Cited by 1,131
Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non–Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique–Groupe Français de Pneumo-Cancérologie NPC 95-01 Study
Fournel, P., Robinet, G., Thomas, P. A., Souquet, P.-J., Léna, H., Vergnenégre, A., Delhoume, J. Y., Treut, J. H. L., Silvani, J.-A., Dansin, É., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.070 · Cited by 543
Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9591-y · Cited by 541
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 452

Show all 22 references

Sorted by citations

Rethinking cancer nanotheranostics
Chen, H., Zhang, W., Zhu, G., Xie, J., & Chen, X. S. (2017) · Nature Reviews Materials · doi:10.1038/natrevmats.2017.24 · Cited by 1,113
Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Nanoparticles of Metal‐Organic Frameworks: On the Road to In Vivo Efficacy in Biomedicine
Simón‐Yarza, T., Mielcarek, A., Couvreur, P., & Serre, C. (2018) · Advanced Materials · doi:10.1002/adma.201707365 · Cited by 661
Polymeric nanoparticles: the future of nanomedicine
Banik, B. L., Fattahi, P., & Brown, J. L. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1364 · Cited by 510
A holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Nanotechnology for Cancer Therapy Based on Chemotherapy
Zhao, C., Cheng, R., Yang, Z., & Tian, Z. (2018) · Molecules · doi:10.3390/molecules23040826 · Cited by 342
PLGA-based nanomedicines manufacturing: Technologies overview and challenges in industrial scale-up
Operti, M. C., Bernhardt, A., Grimm, S., Engel, A., Figdor, C. G., & Tagit, O. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120807 · Cited by 302
Nanoparticles in radiation therapy: a summary of various approaches to enhance radiosensitization in cancer
Kwatra, D., Venugopal, A., & Anant, S. (2013) · Translational Cancer Research · doi:10.21037/1550 · Cited by 299
Mitochondrion‐Anchoring Photosensitizer with Aggregation‐Induced Emission Characteristics Synergistically Boosts the Radiosensitivity of Cancer Cells to Ionizing Radiation
Yu, C. Y. Y., Xu, H., Ji, S., Kwok, R. T. K., Lam, J. W. Y., Li, X., Krishnan, S., Ding, D., & Tang, B. Z. (2017) · Advanced Materials · doi:10.1002/adma.201606167 · Cited by 273
Recent advances in surface decoration of nanoparticles in drug delivery
Ly, P.-D., Ly, K.-N., Phan, H.-L., Nguyen, H. H. T., Duong, V., & Nguyen, H. V. (2024) · Frontiers in Nanotechnology · doi:10.3389/fnano.2024.1456939 · Cited by 265
Nanostructured carriers as innovative tools for cancer diagnosis and therapy
Martinelli, C., Pucci, C., & Ciofani, G. (2019) · APL Bioengineering · doi:10.1063/1.5079943 · Cited by 235
PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution
Hussain, Z., Khan, S., Imran, M., Sohail, M. F., Shah, S. W. A., & de Matas, M. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00631-4 · Cited by 228
Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies
Hu, C. J., Fang, R. H., Luk, B. T., & Zhang, L. (2013) · Nanoscale · doi:10.1039/c3nr05444f · Cited by 208
Early detection of lung cancer biomarkers through biosensor technology: A review
Roointan, A., Mir, T. A., Wani, S. I., Mati-ur-Rehman, Hussain, K. K., Ahmed, B., Abrahim, S., Savardashtaki, A., Gandomani, G., Gandomani, M., et al. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.10.017 · Cited by 198
Polymer nanoparticles for the intravenous delivery of anticancer drugs: the checkpoints on the road from the synthesis to clinical translation
Ferrari, R., Sponchioni, M., Morbidelli, M., & Moscatelli, D. (2018) · Nanoscale · doi:10.1039/c8nr05933k · Cited by 195
Noncovalent interaction-assisted polymeric micelles for controlled drug delivery
Ding, J., Chen, L., Xiao, C., Chen, L., Zhuang, X., & Chen, X. (2014) · Chemical Communications · doi:10.1039/c4cc03153a · Cited by 188
Nanomedicines accessible in the market for clinical interventions
Gadekar, V., Borade, Y., Kannaujia, S., Rajpoot, K., Anup, N., Tambe, V., Kalia, K., & Tekade, R. K. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.034 · Cited by 184
Integrating natural compounds and nanoparticle‐based drug delivery systems: A novel strategy for enhanced efficacy and selectivity in cancer therapy
Manzari‐Tavakoli, A., Babajani, A., Tavakoli, M. M., Safaeinejad, F., & Jafari, A. (2024) · Cancer Medicine · doi:10.1002/cam4.7010 · Cited by 186
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer
Woodman, C. B. J., Vundu, G., George, A., & Wilson, C. M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.009 · Cited by 168
Recent Advances in Nanomicelles Delivery Systems.
Tawfik, S. M., Azizov, S., Elmasry, M. R., Sharipov, M., & Lee, Y.-I. (2020) · Nanomaterials · doi:10.3390/nano11010070 · Cited by 156
“For instance, micelle systems prepared using PCL-b-PEG-b-PCL displayed high loading up to 28% of paclitaxel [83].”
Method
Application of nanotechnology to cancer radiotherapy
Mi, Y., Shao, Z., Vang, J., Kaidar‐Person, O., & Wang, A. Z. (2016) · Cancer Nanotechnology · doi:10.1186/s12645-016-0024-7 · Cited by 155
Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery
Stapleton, S., Jaffray, D. A., & Milosevic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.021 · Cited by 158
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Mathematical modeling in cancer nanomedicine: a review
Dogra, P., Butner, J. D., Chuang, Y.-L., Caserta, S., Goel, S., Brinker, C. J., Vittorio Cristini, C., & Wang, Z. (2019) · Biomedical Microdevices · doi:10.1007/s10544-019-0380-2 · Cited by 154
Novel aspects of encapsulation and delivery using polymersomes
Messager, L., Gaitzsch, J., Chierico, L., & Battaglia, G. (2014) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2014.09.017 · Cited by 142
Nanoparticles for Immune Cytokine TRAIL-Based Cancer Therapy
Guimarães, P. P. G., Gaglione, S. A., Sewastianik, T., Carrasco, R. D., Langer, R., & Mitchell, M. J. (2018) · ACS Nano · doi:10.1021/acsnano.7b05876 · Cited by 139
Focus on Fundamentals: Achieving Effective Nanoparticle Targeting
Tietjen, G. T., Bracaglia, L. G., Saltzman, W. M., & Pober, J. S. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.05.003 · Cited by 134
Surface modification of nano‐drug delivery systems for enhancing antibiotic delivery and activity
Osman, N., Devnarain, N., Omolo, C. A., Fasiku, V. O., Jaglal, Y., & Govender, T. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1758 · Cited by 136
Clinical applications of nanomedicine in cancer therapy
Norouzi, M., Amerian, M., Amerian, M., & Atyabi, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.017 · Cited by 126
Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
Sousa‐Pimenta, M., Estevinho, L. M., Szopa, A., Basit, M., Khan, K., Armaghan, M., Ibrayeva, M., Gürer, E. S., Călina, D. C., Hano, C., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1157306 · Cited by 127
Mesoporous Magnetic Gold “Nanoclusters” as Theranostic Carrier for Chemo-Photothermal Co-therapy of Breast Cancer
Peng, J., Qi, T., Liao, J., Chu, B., Yang, Q., Qu, Y., Li, W., Li, H., Luo, F., & Qian, Z. (2014) · Theranostics · doi:10.7150/thno.7869 · Cited by 119
Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy
Hussain, Z., Rahim, M. A., Jan, N., Shah, H., Rawas‐Qalaji, M., Khan, S., Sohail, M. F., Thu, H. E., Ramli, N. A., Sarfraz, R. M., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.018 · Cited by 120
Dual-Drug Containing Core-Shell Nanoparticles for Lung Cancer Therapy
Menon, J. U., Kuriakose, A. E., Iyer, R., Hernández, E., Gandee, L., Zhang, S., Takahashi, M., Zhang, Z., Saha, D., & Nguyen, K. T. (2017) · Scientific Reports · doi:10.1038/s41598-017-13320-4 · Cited by 113
Impact of formulation on the quality and stability of freeze-dried nanoparticles
Luo, W.-C., Beringhs, A. O., Kim, R., Zhang, W., Patel, S. M., Bogner, R. H., & Lü, X. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.10.014 · Cited by 110
A detailed insight of the tumor targeting using nanocarrier drug delivery system
Batool, S., Sohail, S., Din, F. U., Alamri, A. H., Alqahtani, A. S., Alshahrani, M. A., Alshehri, M. A. S., & Choi, H. G. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2183815 · Cited by 116
Cancer therapy using nanoformulated substances: scientific, regulatory and financial aspects
Alphandéry, E., Grand-Dewyse, P., Lefèvre, R., Mandawala, C., & Durand‐Dubief, M. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1086647 · Cited by 108
PLGA's Plight and the Role of Stealth Surface Modification Strategies in Its Use for Intravenous Particulate Drug Delivery
Sheffey, V. V., Siew, E. B., Tanner, E. E. L., & Eniola‐Adefeso, O. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101536 · Cited by 103
Nanoparticles in radiation oncology: From bench-side to bedside
Rancoule, C., Magné, N., Vallard, A., Guy, J., Rodriguez‐Lafrasse, C., Deutsch, É., & Chargari, C. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.011 · Cited by 96
Triple negative breast cancer and non-small cell lung cancer: Clinical challenges and nano-formulation approaches
Ghosh, S., Javia, A., Shetty, S. R., Bardoliwala, D., Maiti, K., Banerjee, S., Khopade, A. J., Misra, A. R., Sawant, K. K., & Bhowmick, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.07.014 · Cited by 95
Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders
Salvalaio, M., Rigon, L., Belletti, D., D’Avanzo, F., Pederzoli, F., Ruozi, B., Marin, O., Vandelli, M. A., Forni, F., Scarpa, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156452 · Cited by 93
Supramolecular Nanofibers of Curcumin for Highly Amplified Radiosensitization of Colorectal Cancers to Ionizing Radiation
Xu, H., Wang, T., Yang, C., Li, X., Liu, G., Yang, Z., Singh, P. K., Krishnan, S., & Ding, D. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707140 · Cited by 93
Micellar carriers for the delivery of multiple therapeutic agents
Thipparaboina, R., Chavan, R. B., Kumar, D. K., Modugula, S., & Shastri, N. R. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.07.046 · Cited by 93
Evolution of nanomedicine formulations for targeted delivery and controlled release
Puri, S., Mazza, M., Roy, G., England, R., Zhou, L., Nourian, S., & Subramony, J. A. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114962 · Cited by 94
Bio-based nanomaterials for cancer therapy
Li, Y., Zheng, X., & Chu, Q. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101134 · Cited by 89
Tumor Radiosensitization by Monomethyl Auristatin E: Mechanism of Action and Targeted Delivery
Buckel, L., Savariar, E. N., Crisp, J. L., Jones, K. A., Hicks, A. M., Scanderbeg, D. J., Nguyen, Q. T., Sicklick, J. K., Lowy, A. M., Tsien, R. Y., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1931 · Cited by 87
pH‐Sensitive Dissociable Nanoscale Coordination Polymers with Drug Loading for Synergistically Enhanced Chemoradiotherapy
Liu, J., Wang, H., Yi, X., Chao, Y., Geng, Y., Xu, L., Yang, K., & Liu, Z. (2017) · Advanced Functional Materials · doi:10.1002/adfm.201703832 · Cited by 85
Nanotechnology: Breaking the Current Treatment Limits of Lung Cancer
Li, S., Xu, S., Liang, X., Xue, Y., Mei, J., Ma, Y., Liu, Y., & Liu, Y. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202100078 · Cited by 86
Nanomaterials in anticancer applications and their mechanism of action - A review
Das, C. G. A., Kumar, V. G., Dhas, T. S., Karthick, V., & Kumar, C. M. V. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102613 · Cited by 84
Precise nanoscale fabrication technologies, the “last mile” of medicinal development
Bi, Y., Xie, S., Li, Z., Dong, S., & Teng, L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.03.040 · Cited by 90
Engineering Tumor-Targeting Nanoparticles as Vehicles for Precision Nanomedicine
Gonda, A., Zhao, N., Shah, J. V., Calvelli, H. R., Kantamneni, H., Francis, N. L., & Ganapathy, V. (2019) · Med One · doi:10.20900/mo.20190021 · Cited by 83
Using PEGylated magnetic nanoparticles to describe the EPR effect in tumor for predicting therapeutic efficacy of micelle drugs
Chen, L., Zang, F., Wu, H., Li, J., Xie, J., Ma, M., Gu, N., & Zhang, Y. (2017) · Nanoscale · doi:10.1039/c7nr08319j · Cited by 79
Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy
Qu, X., Zhou, D. F., Lu, J., Qin, D., Zhou, J. M., & Liu, H.-J. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.12.010 · Cited by 78
Improving the Phototherapeutic Efficiencies of Molecular and Nanoscale Materials by Targeting Mitochondria
Lin, F., Bao, Y.-W., & Wu, F. (2018) · Molecules · doi:10.3390/molecules23113016 · Cited by 77
Alleviating the hypoxic tumor microenvironment with MnO2-coated CeO2 nanoplatform for magnetic resonance imaging guided radiotherapy
Pi, F., Deng, X., Xue, Q., Zheng, L., Liu, H., Yang, F., & Chen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01850-1 · Cited by 76
Engineering folate-targeting diselenide-containing triblock copolymer as a redox-responsive shell-sheddable micelle for antitumor therapy in vivo
Behroozi, F., Abdkhodaie, M.-J., Abandansari, H. S., Satarian, L., Molazem, M., Al‐Jamal, K. T., & Baharvand, H. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.031 · Cited by 73
Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation
Kelishady, P. D., Saadat, E., Ravar, F., Javar, H. A., & Dorkoosh, F. A. (2014) · Pharmaceutical Development and Technology · doi:10.3109/10837450.2014.965323 · Cited by 69
Insights on Development Aspects of Polymeric Nanocarriers: The Translation from Bench to Clinic
Tewari, A. K., Upadhyay, S. C., Kumar, M., Pathak, K., Kaushik, D. K., Verma, R., Bhatt, S., Massoud, E. E. S., Rahman, M. H., & Cavalu, S. D. (2022) · Polymers · doi:10.3390/polym14173545 · Cited by 74
The role of recent nanotechnology in enhancing the efficacy of radiation therapy
Bergs, J. W. J., Wacker, M. G., Hehlgans, S., Piiper, A., Multhoff, G., Rödel, C. M., & Rödel, F. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.008 · Cited by 71
Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: A biodistribution study
Monteiro, L. O. F., Fernandes, R. S., Oda, C. M. R., Lopes, S. C. D. A., Townsend, D. M., Cardoso, V. N., Oliveira, M. C., Leite, E. A., Rubello, D., & de Barros, A. L. B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.135 · Cited by 67
Nanomedicine: is It Lost in translation?
Greish, K. F., Mathur, A., Bakhiet, M., & Taurin, S. (2018) · Therapeutic Delivery · doi:10.4155/tde-2017-0118 · Cited by 67
Controlled-release nanotherapeutics: State of translation
Tan, Y., Lao, L. L., Xiong, G. M., & Venkatraman, S. S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.06.014 · Cited by 66
Advances in Delivery of Chemotherapeutic Agents for Cancer Treatment
Yadav, A., Singh, S., Sohi, H., & Dang, S. (2021) · AAPS PharmSciTech · doi:10.1208/s12249-021-02174-9 · Cited by 64
Pediatric Drug Development: Reviewing Challenges and Opportunities by Tracking Innovative Therapies
Domingues, C., Jarak, I., Veiga, F., Dourado, M., & Figueiras, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15102431 · Cited by 69
Reversible stimuli-responsive nanomaterials with on-off switching ability for biomedical applications
Alejo, T., Usón, L., & Arruebo, M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.036 · Cited by 63
Potential Applications of Nanoparticles in Improving the Outcome of Lung Cancer Treatment
Girigoswami, A., & Girigoswami, K. (2023) · Genes · doi:10.3390/genes14071370 · Cited by 63
Nanotechnology in Radiation Oncology
Wang, A. Z., & Tepper, J. E. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.0699 · Cited by 61
Milk exosomes: an oral drug delivery system with great application potential
Tian, M., Hao, D.-X., Liu, Y., He, J. M., Zhao, Z.-H., Guo, T.-Y., Li, X., & Zhang, Y. (2023) · Food & Function · doi:10.1039/d2fo02013k · Cited by 61
Micellar Stability in Biological Media Dictates Internalization in Living Cells
Feiner‐Gracia, N., Buzhor, M. G., Fuentes, E., Pujals, S., Amir, R. J., & Albertazzi, L. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08351 · Cited by 60
Enhancement of radiotherapy efficacy by docetaxel-loaded gelatinase-stimuli PEG-Pep-PCL nanoparticles in gastric cancer
Cui, F., Li, R., Liu, Q., Wu, P.-Y., Hu, W., Yue, G., Ding, H., Li-xia, Y., Qian, X.-P., & Liu, B.-R. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.002 · Cited by 61
Beyond Formulation: Contributions of Nanotechnology for Translation of Anticancer Natural Products into New Drugs
Miguel, R. D. A., Hirata, A. S., Jimenez, P. C., Lopes, L. B., & Costa-Lotufo, L. V. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081722 · Cited by 61
Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy
Zhao, J., Zhou, M., & Li, C. (2016) · Cancer Nanotechnology · doi:10.1186/s12645-016-0022-9 · Cited by 57
Pharmacokinetics of nanotechnology-based formulations in pediatric populations
Yellepeddi, V., Joseph, A., & Nance, E. A. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.08.008 · Cited by 67
Synthesis and characterization of chitosan-grafted-polycaprolactone micelles for modulate intestinal paclitaxel delivery
Almeida, A., Silva, D., Gonçalves, V. M. F., & Sarmento, B. F. C. C. (2017) · Drug Delivery and Translational Research · doi:10.1007/s13346-017-0357-8 · Cited by 55
Application of nanomedicine in radiotherapy sensitization
Song, X., Sun, Z., Li, L., Zhou, L., & Yuan, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1088878 · Cited by 52
Extracellular Vesicles in Modifying the Effects of Ionizing Radiation
Szatmári, T., Hargitai, R., Sáfrány, G., & Lumniczky, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225527 · Cited by 52
Investigating the Influence of Aromatic Moieties on the Formulation of Hydrophobic Natural Products and Drugs in Poly(2-oxazoline)-Based Amphiphiles
Hahn, L., Lübtow, M. M., Lorson, T., Schmitt, F., Appelt‐Menzel, A., Schobert, R., & Luxenhofer, R. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00708 · Cited by 56
Craft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity
Bhattacharjee, S. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00033 · Cited by 53
Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Martins, P. H. D. F., Rosa, D., Fernandes, A. R., & Baptista, P. V. (2014) · Current Nanomedicine · doi:10.2174/1877912304666140304000133 · Cited by 52
Clinical Applications of Targeted Nanomaterials
Kumar, A., Shahvej, S., Yadav, P. K., Modi, U., Yadav, A. K., Solanki, R., & Bhatia, D. D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17030379 · Cited by 53
Integrating nanomedicine into clinical radiotherapy regimens
DuRoss, A. N., Neufeld, M. J., Rana, S. R., Thomas, C. R., & Sun, C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.002 · Cited by 49
Advancements in nanoparticles for skin care: a comprehensive review of properties, applications, and future perspectives
Chakraborty, S. S., Panja, A., Dutta, S., & Patra, P. (2024) · Discover Materials · doi:10.1007/s43939-024-00088-4 · Cited by 48
Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells
Zhou, J., Sun, M., Jin, S., Fan, L., Zhu, W., Sui, X., Cao, L., Yang, C., & Han, C. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1580799 · Cited by 48
The use of nanomaterials in advancing photodynamic therapy (PDT) for deep-seated tumors and synergy with radiotherapy
Dinakaran, D., & Wilson, B. C. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1250804 · Cited by 48
Immunoliposomes as an emerging nanocarrier for breast cancer therapy
Parveen, N., Abourehab, M. A. S., Shukla, R., Veeraveedu, P. T., Jain, G. K., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111781 · Cited by 48
Nanomedicine and drug delivery: A comprehensive review of applications and challenges
Singh, K., Singhal, S., Pahwa, S., Sethi, V. A., Sharma, S., Singh, P., Kale, R. D., Ali, S. W., & Sagadevan, S. (2024) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2024.101403 · Cited by 50
2‐Methyltetrahydrofuran ( 2‐MeTHF ) as a versatile green solvent for the synthesis of amphiphilic copolymers via ROP , FRP , and RAFT tandem polymerizations
Englezou, G., Kortsen, K., Pacheco, A. A. C., Cavanagh, R. J., Lentz, J. C., Krumins, E., Sanders, C., Howdle, S. M., Nedoma, A. J., & Taresco, V. (2020) · Journal of Polymer Science · doi:10.1002/pol.20200183 · Cited by 46
Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines
Ao, L., Reichel, D., Hu, D., Jeong, H., Kim, K. B., Bae, Y., & Lee, W. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.226993 · Cited by 46
Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery
Tian, X., Lara, H., Wagner, K., Saripalli, S., Hyder, S. N., Foote, M. B., Sethi, M., Wang, E. C., Caster, J. M., Zhang, L., et al. (2015) · Nanoscale · doi:10.1039/c5nr05869d · Cited by 45
Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer
Gadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060524 · Cited by 46
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy
Liu, N., Wang, X., Wang, Z., Yonemori, K., Fang, Y., Gao, J., Kong, X., & Wang, J. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01692-4 · Cited by 49
Targeted nanomedicines for the treatment of bone disease and regeneration
Ordikhani, F., Zandi, N., Mazaheri, M., Luther, G. A., Ghovvati, M., Akbarzadeh, A., & Annabi, N. (2020) · Medicinal Research Reviews · doi:10.1002/med.21759 · Cited by 45
Strategies for the design of nanoparticles: starting with long-circulating nanoparticles, from lab to clinic
Wang, R., Zhang, Z., Liu, B., Xue, J., Liu, F., Tang, T., Liu, W., Feng, F., & Qu, W. (2021) · Biomaterials Science · doi:10.1039/d0bm02221g · Cited by 46
An electrochemical CD59 targeted noninvasive immunosensor based on graphene oxide nanoparticles embodied pencil graphite for detection of lung cancer
Deepa, Nohwal, B., & Pundir, C. (2020) · Microchemical Journal · doi:10.1016/j.microc.2020.104957 · Cited by 42
In vivo synergistic anti-tumor effect of paclitaxel nanoparticles combined with radiotherapy on human cervical carcinoma
Yu, Y., Xu, S., You, H., Zhang, Y., Yang, B., Sun, X., Yang, L., Chen, Y., Fu, S., & Wu, J. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1230902 · Cited by 39
Poly(vinyl methyl ether/maleic anhydride)-Doped PEG–PLA Nanoparticles for Oral Paclitaxel Delivery To Improve Bioadhesive Efficiency
Wang, Q., Li, C., Ren, T., Chen, S., Ye, X., Guo, H., He, H., Zhang, Y. X., Yin, T., Liang, X., et al. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00612 · Cited by 39
Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies
Sun, W., Deng, Y., Zhao, M., Jiang, Y. Y., Gou, J., Wang, Y., Yin, T., Zhang, Y. X., He, H., & Tang, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.01.010 · Cited by 42
Trends in smart drug delivery systems for targeting cancer cells
Kandula, S., Singh, P. K., Kaur, G. A., & Tiwari, A. (2023) · Materials Science and Engineering B · doi:10.1016/j.mseb.2023.116816 · Cited by 38
Bio-nanomaterials: Promising anticancer properties and treatment strategies
Elemike, E. E., Onunkwo, I. C., Ughumiakpor, O., Alawuru, F., Mukoro, A., Ishom, P., Obarakpor, F., Hossain, I., & Aziza, A. E. (2025) · Nano TransMed · doi:10.1016/j.ntm.2025.100076 · Cited by 42
Unveiling the potential of ursolic acid modified hyaluronate nanoparticles for combination drug therapy in triple negative breast cancer
Sharma, R., Yadav, V. R., Jha, S., Dighe, S., & Jain, S. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122196 · Cited by 37
Production of paclitaxel-loaded PEG-b-PLA micelles using PEG for drug loading and freeze-drying
Rasoulianboroujeni, M., Repp, L., Lee, H. J., & Kwon, G. S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.08.032 · Cited by 38

Authors: Werner, M. E., Cummings, N. D., Sethi, M., Wang, E. C., Sukumar, R., Moore, D. T., & Wang, A. Z.
Affiliations: University of North Carolina at Chapel Hill (US)
Corresponding author: Wang, Andrew Z.
ORCID: Werner, Michael E.
Sethi, Manish
Wang, Edina C.
Wang, Andrew Z.
Venue: International Journal of Radiation Oncology*Biology*Physics
Publisher: Elsevier BV
Published: 2013-07
Volume: 86
Issue: 3
Pages: 463-468
ISSN: 0360-3016 (ISSN-L)
DOI: 10.1016/j.ijrobp.2013.02.009
PMC: PMC3750707
OpenAlex: W2169498622
Cited by: 267
References: 22
Citations by year: 2026: 20 · 2025: 23 · 2024: 21 · 2023: 31 · 2022: 24 · 2021: 18 · 2020: 23 · 2019: 18 · 2018: 23 · 2017: 19 · 2016: 22 · 2015: 12 · 2014: 8 · 2013: 4
FWCI: 5.85
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: International Journal of Radiation Oncology*Biology*Physics (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5u54ca151652-05, 2k12ca120780-16)
National Cancer Institute (5-K12-CA120780-01-05, U54‐CA151652, 1-U54-CA151652-01, K12-CA120780, R01CA178748)
Topics: Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords: paclitaxel, nanoparticle drug delivery, radiosensitizers, non-small cell lung cancer, chemoradiotherapy, controlled drug release, nanoparticle size and surface charge, taxol comparison
MeSH terms: Animals, Antineoplastic Agents, Phytogenic, Carcinoma, Non-Small-Cell Lung, Lung, Lung Neoplasms, Mice, Nude, Polymers, Radiation-Sensitizing Agents, Paclitaxel, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tumor Burden, Mice, Nanoparticles, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Preclinical Evaluation of Genexol-PM, a Nanoparticle Formulation of Paclitaxel, as a Novel Radiosensitizer for the Treatment of Non-Small Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks